# Comprehensive Bioinformatics Analysis and Experimental Verification RNF186 Is a Recurrence Signature Gene of Hepatocellular Carcinoma that Promotes Cell Proliferation

## TL;DR

This study identifies RNF186 as a gene linked to liver cancer recurrence and shows it promotes cancer cell growth, offering new insights for precision treatment.

## Contribution

Novel identification of RNF186 as a recurrence signature gene in HCC with experimental validation of its role in cell proliferation.

## Key findings

- A risk model stratified HCC patients into high- and low-risk groups with distinct survival outcomes.
- RNF186 was identified as an independent prognostic gene promoting HCC cell proliferation.
- High-risk patients showed altered immune profiles and reduced immunotherapy response.

## Abstract

Tumor recurrence is a major determinant of poor prognosis in hepatocellular carcinoma (HCC), yet its cellular and molecular basis remains incompletely understood. This study aimed to identify recurrence-associated genes at single-cell resolution and to develop a prognostic model for predicting survival outcomes and immunotherapy responsiveness in HCC.

Single-cell RNA sequencing data from 12 primary and 6 recurrent HCC samples were integrated and analyzed to identify genes characteristic of recurrence. After quality control, principal component analysis, and t-SNE-based clustering were used to identify highly variable genes for cell clustering and annotation. Based on macrophage characteristic genes, a recurrence-related risk score was constructed using a LASSO-Cox regression model, and a nomogram integrating clinical variables was developed. Prognostic performance was assessed using Kaplan–Meier analysis and time-dependent ROC curves. Immune infiltration profiling was performed to compare immune characteristics between risk groups defined by the prognostic model. Multivariate Cox regression was applied to identify independent prognostic biomarkers, which were subsequently validated by cell function experiments.

The risk model effectively stratified patients into high- and low-risk groups with distinct survival outcomes, demonstrating high predictive accuracy for 1-, 3-, and 5-year survival. High-risk patients showed altered immune profiles and a reduced predicted response to immunotherapy. GRID2, RNF186, and SLC4A10 were identified as independent prognostic genes, with RNF186 promoting HCC cell proliferation in a SESN2-dependent manner.

This prognostic model provides new insights into precision medicine and immunotherapy for HCC, highlighting the potential clinical significance of RNF186 as a therapeutic target.